Abstract
dc:description.abstractThree aspects of the drug development process are little understood in the literature: 1) which type of organization has comparative advantage in conducting clinical trials, firms or nonprofit organization (NPOs)?; 2) what determines the timing of technological collaboration?; and 3) how the strategies making, allying, and buying R&D impact the probability of drug approval? Using data on over 20,000 clinical trials, 800 technological alliances, and 14,000 R&D projects, the main findings of this econometric study are: 1) firms complete each phase of clinical trial faster than nonprofit organizations; 2) licensor scientific and technological specialization is the main factor to speed up the technological collaboration; and 3) R&D projects developed by research alliance have higher probability of drug approval than internal R&D projects, but R&D projects originated from M&A have lower probability of drug approval than internal R&D projects. Together these findings inform policy makers and managers on how to foster the innovation performance in the biopharmaceutical industry.
Degree
thesis:*- Level thesis:degree_level
- Doctoral
- Department dc:contributor.department
- Economics
- Grantor dc:publisher
- Georgia Institute of Technology
- Year dc:date.issued
- 2017
Author and committee
dc:creator, dc:contributor.*- Author dc:creator
-
- Kamada, Vitor
- Advisor dc:contributor.advisor
-
- Nair-Reichert, Usha
- Committee members dc:contributor.committeemember
-
- Kutlu, Levent
- McCarthy, Patrick S.
- Klimenko, Mikhail
- Barke, Richard
Subjects
dc:subject × 8Rights
- Language dc:language.iso
- en_US
Identifiers
dc:identifier.*- Handle dc:identifier.uri
- http://hdl.handle.net/1853/58684